April 15, 2019
Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study
The primary endpoint is the percent reduction in urinary oxalate frombaseline to six months. The Company expects to report initialILLUMINATE-B results in mid-2020.